Company profile
Maravai LifeSciences Holdings, Inc.
NASDAQ: MRVI · Healthcare · Biotechnology
#296 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
53DFH 60DQ 44GM 46SS 64
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ revenue growth (YoY), listing tenure
Methodology →Revenue TTM
$204.7M
Rev growth YoY (TTM)
-15.4%
Net income (FY)
-$130.8M
Employees
435
as of 2026-08-09
Market cap
$1.7B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$185.7M$185.7M2025
Net income-$130.8M-$130.8M2025
Operating income-$215.3M-$215.3M2025
Total assets$770.6M$770.6M2025
Liabilities$397.9M$397.9M2025
Equity$212.4M$212.4M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Shipping and Handling100%
By geography
North America61%
Asia Pacific22%
EMEA17%
Latin And Central America1%
The read
What is Maravai LifeSciences Holdings, Inc.’s revenue?
Maravai LifeSciences Holdings, Inc. booked $185.7M in FY2025 revenue, contracting 28% year over year — slower than 75% of Healthcare companies we track, at a -70.4% net margin.
Peers · Healthcare
LifeMD, Inc.73Bbiote Corp.63CRhythm Pharmaceuticals, Inc.60CStoke Therapeutics, Inc.60CHeartflow, Inc. Common Stock44DPhathom Pharmaceuticals, Inc.47DNeighbors
San Diego →Key facts
CEOBernd Brust
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: MRVI
Employees435
IPO date2020-11-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.